
Torii has gathered a great deal of inspiration from its Danish partner ALK-Abello in designing the phase 2/3 studies the Japanese company initiated Tuesday.
“It not only looks like them, it is an exact copy of the studies we are running in Europe, because there are two primary end-points in the study in order to get as broad an indication as possible. One arm focuses on hay fever and the other one asthma, and of course it is important, to a Japanese company as well as a European one, to get as broad an indication area as possible,” CEO of ALK, Jens Bager, tells Medwatch.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app